Hepatitis Transmission Risk in Kidney Transplantation (the HINT study)
- 1 January 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (1) , 146-153
Abstract
Interpreting hepatitis serology and virus transmission risk in transplantation can be challenging. Decisions must balance opportunity to transplant against potential infection transmission. We aimed to survey understanding among the Australian and New Zealand medical transplant workforce of hepatitis risk in kidney donors and recipients. An anonymous, self-completed, cross-sectional survey was distributed via electronic mailing lists to Australian and New Zealand clinicians involved in kidney transplantation (2014-2015). We compared interpretation of clinical scenarios with paired donor and recipient hepatitis B and C (HBV, HBC) serology to recommendations in clinical practice guidelines. We used logistic regression modelling to investigate characteristics associated with decisions on transplant suitability in scenarios with poor (<50%) guideline concordance (odds ratios, OR). 110 respondents had representative workforce demographics: most were male (63%) nephrologists (74%) aged 40-49. While donor and recipient hepatitis status was largely well understood, transplant suitability responses varied among respondents. For an HBV surface antigen positive donor and vaccinated recipient, 44% suggested this was unsuitable for transplant (guideline concordant) but 35% suggested this was suitable with prophylaxis (guideline divergent). In 4 scenarios with transplant suitability guideline concordance <50%, acute transplant care involvement predicted guideline concordant responses (OR 1.69, p=0.04). Guideline concordant responses were chosen less by hepatologists, intensive care doctors (OR 0.23, 0.35 respectively, p=0.01), and New Zealanders (guideline concordant responses OR 0.17, p<0.01; alternative responses OR 4.31, p<0.01). Despite broadly consistent interpretations of hepatitis serology, transplant suitability decisions varied, and often diverged from guidelines. Improved decision support may reduce clinician variability.Keywords
This publication has 22 references indexed in Scilit:
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialThe Lancet Infectious Diseases, 2016
- An Interferon-free Antiviral Regimen for HCV after Liver TransplantationNew England Journal of Medicine, 2014
- Renal transplantation from hepatitis B surface antigen (HBsAg)‐positive donors to HBsAg‐negative recipients: a case of post‐transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literatureTransplant Infectious Disease, 2013
- Donor-Derived Infections in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Screening of Donor and Recipient in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Organ donor screening using parallel nucleic acid testing allows assessment of transmission risk and assay results in real timeTransplant Infectious Disease, 2012
- Transmission of Human Immunodeficiency Virus and Hepatitis C Virus From an Organ Donor to Four Transplant RecipientsAmerican Journal of Transplantation, 2011
- High infectious risk donors: what are the risks and when are they too high?Current Opinion in Organ Transplantation, 2011
- Donors Positive for Hepatitis B Core Antibodies in Nonliver TransplantationsTransplantation Proceedings, 2011
- Nucleic Acid Testing (NAT) of Organ Donors: Is the ‘Best’ Test the Right Test? A Consensus Conference ReportAmerican Journal of Transplantation, 2010